The majority of urothelial neoplasms are superficial bladder carcinoma, the prognosis of which cannot be evaluated with current parameters. Several studies have tried to isolate one or more reliable markers. Although some results are satisfactory these markers have not however been used in the clinical practice. The Authors investigate recent reports, quoting those that, in their opinion, are the most interesting.
RussellPamela J., PlomleyJ., FaghavanD.: The use of monoclonal antibodis for the diagnosis and therapy of bladder cancer. Brit. Urol., 71: 121–129, 1993.
2.
FradetY., TardifM., BourgetL., RobertJ., Lavai University Urology Group: Clinical cancer progression in urinary bladder tumours evaluated by multiparameter flow cytometry with monoclonal antibodies. Cancer Res., 50: 432–437, 1990.
3.
OkamureK., MiyakeK., AsaiJ.: Growth fractions of transitional cell carcinomas of the bladder defined by monoclonal antibody Ki-67. J. Urol., 144: 875–878, 1990.
4.
MoutzourisG., YannopaulosD., BarbatisC., ZaharofA., TheodorouC.H.: Is beta-human chorionic gonadotropin production by TCC of the bladder a marker aggressive disease and resistance to radiotherapy?Brit. J. Urol., 72: 907–909, 1993.
5.
HulandH., SchneiderA.W., HulandE.: Sesitivity of urinary quantitative immunocitology with monoclonal antibody 486P3/12 in 241 unselected patients with bladder carcinoma. J. Urol., 145: 495–497, 1991.
6.
SheinfeldJ., ReuterVictor E., Myron MelamedR., William FairR., MorseM., Pramod SoganiC., Harry HerrW., WhitmoreWillet F., and Cordon-CardoC.: Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J. Urol., 113: 285–288, 1990.
7.
HulandE., HulandH., SchneiderA.W.: Quantitative immunocytology in the management of patients with superficial bladder carcinoma. A marker to identify patients who do not require prophylaxis. J. Urol., 144: 637–610, 1990.
8.
HeinzerH., HulandE., MonkM., HulandH.: Distribution of 486P3/12 antigen, blood group antigen and T antigen in cystectomy specimens from patients with stage T2 transitional cell carcinoma of the bladder. J. Urol., 148: 802–805, 1992.
9.
MessingM.E.: Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res., 50: 2530–2537, 1990.
10.
HuffmanJ.L., FradetY., Cordon-CardoC.: Effect of intravesical Bacillus Calmette-Guerin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder. Cancer Res., 45: 4201–4204, 1985.
11.
FlamT.A., ChopinD.K., LeleuC.: Immunohistochemical markers defined by monoclonal antibodies and response to Bacillus Calmette-Guerin endovesical immunotherapy for superficial bladder tumours. Eur. Urol., 17: 338–342, 1990.
12.
FalorW.H., Ward-SkinnerR.M.: The importance of marker chromosomes in superficial transitional cell carcinoma of the bladder: 50 patients followed-up to 17 years. J. Urol., 139: 929–933, 1988.
13.
MicicS., MicicM., MilasinJ.: Chromosome analysis in patients with bladder tumour. Urol. Int., 13: 201–205, 1988.
14.
KnowlesM.A., CainsJ.P., WilliamsonM.P., ProctorA.J., CoombsL.M., EydmannM.E.: Identification of multiple molecular genetic alterations in bladder cancer. Cancer Genet. Cytogenet., 63: 140 abstract, 1992.
15.
SantosE., TonicS.R., AaronsonS.A.: T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of Balbe-and Harvey-MSV trasforming genes. Nature, 298: 343–347, 1982.
16.
FujitaJ., SrivastavaS.K., PonderB.A.J.: Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumours. Proc. Natl. Acad. Sci. USA, 82: 3849–3853, 1985.
17.
MoryamaM., AkiyamaT., YamamotoT., KawamotoT., KatoT., Sato HikageT., KatsutaN., MoriS.: Expression of C-erbB-2 gene product in urinary bladder cancer. J. Urol., 145: 423–427, 1991.
18.
CoombsL.M., PigottD., SweeneyE., ProctorA.S., EydmannM.E., ParkinsonC., KnowlesM.A.: Amplification and over-expression of C-erbB-2 in transitional cell carcinoma of the urinary bladder. Brit. J. Cancer, 6: 423, 1991.
19.
WoodD.P.Jr., FairW.R., ChagantiR.S.K.: Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer. J. Urol., 147: 274, 1992.
20.
SidranskyD., EschenbachA.V., TsaiI.C., YonesP., SummerhayesI., MarshallF., PaulM., GreenP., HamiltonS.R., FrostP., VolgeistenB.: Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252: 706, 1991.
21.
SeigneJ.D., DaytonS.H., ZhangD.S., SgroiD., GriffinP.P., LinC.W., ShipleyW.U., HeneyN.M., McDougalW.S., YandellD.W.: The p53 tumour suppressor gene as a potential prognostic marker in invasive bladder cancer. J. Urol., 147 (2): 338A, abstract 504, 1992.
22.
FujimotoK., YamadaY., OkajimaE., KakizoeT., SasakiH., SugimuraT., TeradaM.: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res., 52: 1393, 1992.
23.
UedaK., CornwellN.M., GottesmanM.M.: The mdr-1 gene, responsible for multidrug-resistance codes for P.glycoprotein. Biochem. Biophys. Res. Commun., 141: 956–962, 1986.
24.
DaltonW.S., GroganT.M., MeltezerT.S.: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil tochemotherapy. J. Clin. Oncol., 7: 415–424, 1989.
